Browse

Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer

Cited 4 time in Web of Science Cited 4 time in Scopus
Authors
Kim, Kyubo; Chie, Eui Kyu; Jang, Jin-Young; Kim, Sun Whe; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue; Ha, Sung W
Issue Date
2008-12-09
Publisher
Oxford University Press
Citation
Jpn J Clin Oncol. 2009 Feb;39(2):111-5. Epub 2008 Dec 5.
Keywords
AdultAgedAntiemetics/*therapeutic useBenzimidazoles/*therapeutic useBiliary Tract Neoplasms/*drug therapyChemotherapy, Adjuvant/*adverse effectsFemaleFluorouracil/*administration & dosageHumansMaleMetoclopramide/therapeutic useMiddle AgedNausea/physiopathology/*prevention & controlOndansetron/therapeutic usePancreatic Neoplasms/*drug therapyRadiotherapy, Adjuvant/*adverse effectsVomiting/physiopathology/*prevention & control
Abstract
OBJECTIVE: The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy. METHODS: Between November 2006 and April 2007, 25 patients with pancreatico-biliary cancer underwent adjuvant chemoradiotherapy. A total dose of 40 Gy was delivered using 2 Gy/fraction, 5 days a week, with 2 weeks of planned rest after 20 Gy. Concomitant 5-fluorouracil (500 mg/m(2)/day i.v. bolus) was administered for the first 3 days of each split course. During the first course of chemoradiotherapy, all patients had prophylactic metoclopramide before treatment and those refractory to metoclopramide received rescue medication with ondansetron. During the second course of chemoradiotherapy, prophylactic ramosetron was given to patients who were refractory to ondansetron. Response to antiemetics was scored in four tiers: none, no CRINV; mild, did not interfere with normal daily life; moderate, interfered with normal daily life and severe, patient bedridden because of CRINV. RESULTS: Fifty-six percent of the patients (14 of 25) had moderate CRINV despite metoclopramide, and received ondansetron. Ten patients who experienced moderate CRINV despite the ondansetron had prophylactic ramosetron, and 60% of the patients (6 of 10) had the symptom improved. CONCLUSIONS: Ramosetron proved to be an effective alternative for the control of CRINV during upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy.
ISSN
1465-3621 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19060294

http://jjco.oxfordjournals.org/cgi/reprint/39/2/111.pdf

https://hdl.handle.net/10371/46133
DOI
https://doi.org/10.1093/jjco/hyn140
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse